CN100406026C - Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method - Google Patents
Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method Download PDFInfo
- Publication number
- CN100406026C CN100406026C CNB2004100708435A CN200410070843A CN100406026C CN 100406026 C CN100406026 C CN 100406026C CN B2004100708435 A CNB2004100708435 A CN B2004100708435A CN 200410070843 A CN200410070843 A CN 200410070843A CN 100406026 C CN100406026 C CN 100406026C
- Authority
- CN
- China
- Prior art keywords
- medicine
- ethanol
- water
- extract
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Abstract
The present invention discloses a medicine for treating chronic gastritis and gastric cancer and a preparation method thereof. The medicine of the present invention comprises water extractant of inonotus obliquus, and the water extractant is made by that inonotus obliquus sporophores are refluxed and extracted by water at a temperature of 80 DEG C to 90 DEG C. The preparation method comprises the following procedures: 1), the water extract is made by that the inonotus obliquus sporophores are refluxed and extracted by water at a temperature of 80 DEG C to 90 DEG C, and the water extractant is obtained by drying the water extract; 2), ethanol extract is obtained by refluxing the inonotus obliquus sporophores which are left in procedure 1) by ethanol at a temperature of 70 DEG C to 80 DEG C, and ethanol extractant is obtained by evaporating solvent; 3), the medicine is obtained by mixing the water extractant which is obtained in procedure 1) and the ethanol extractant which is obtained in procedure 2) according to the share proportion by weight of 1.5 to 2.5:1. The medicine of the present invention can effectively improve body immunity without any side effect, and has significant therapeutic effect on gastritis, gastric cancer, etc. The medicine of the present invention has the advantages of broad raw material resource, simple preparation method, low cost and broad clinical practicability and economic value.
Description
Technical field
The present invention relates to Chinese medicine and preparation method thereof, particularly relate to a kind of medicine for the treatment of chronic gastritis, gastric cancer and preparation method thereof.
Background technology
Gastric cancer is one of malignant tumor that sickness rate is the highest in the world, and pilosity is born in the crowd of relatively poor area of social economy's level or happiness food cure foods.At present, the mortality rate of gastric cancer has occupy first of China's malignant tumor, prevents and treats gastric precancerous lesion effectively, blocks it and develops to cancer, is prevention gastric cancer, the essential measure that reduces its sickness rate and means.Studies show that the sickness rate of superficial gastritis, atrophic gastritis patient gastric cancer is dangerous significantly to be increased.Wherein, atrophic gastritis companion forme fruste intestinalization give birth to and in, the severe atypical hyperplasia is that real precancerous lesion has been undisputable fact.Gastric mucosa generation canceration has the process of a differentiation, that is: chronic gastritis develops into gastric mucosa atrophy, develops into intestinalization again and gives birth to, and develops into dysplasia again, develops into gastric cancer again.Modern medicine thinks that gastric precancerous lesion is relevant with factors such as environment, immunity degradation, chronic alcoholism, bile refluxs.The inactivation of oncogene activation and antioncogene is tumorigenic molecular basis, C-Ha-ras wherein, and cerb β-2, hast, multiple oncogene active such as EGFP and antioncogene P53 inactivation have participated in the formation and development of gastric cancer.Relevant gastric cancer origin cause of formation modern medicine thinks that also the change of gastritis is directly proportional with the gradient of infection of helicobacter pylori (HP), and dysplasia is relevant with the infection of inflammation or helicobacter pylori.This is because the existence of HP causes the stomach lining inflammation reaction, repetitious stimulation and cause mucous epithelium generation dysplasia.The present doctor trained in Western medicine of relevant chronic gastritis lacks ideal Therapeutic Method.Mainly adopt operation for the gastric cancer western medicine, the treatment of methods such as radiotherapy, chemotherapy though can obtain certain curative effect, when many patients treat that clinical diagnosis is clear and definite, has lost the preferable opportunity of operative treatment, can only rely on non-operative treatment.Modern times put, chemotherapy is bigger to side effect such as bone marrow immunologic function, hepatic and renal functions, so that many patients are difficult to accept and adhere to.Chinese medicine has shown unique effect and advantage on such treatment of diseases.Chinese pharmaceutical enterprises according to tradition side's medicine develop multiple Chinese patent medicine such as stomach wither peace electuary, the flat side of withering, the powder for curing gastritis that disappears, change life and preapre for an unfavorable turn of events clever I number etc.These medicines to the effective percentage of chronic gastritis all more than 80%.As wither different soup (Radix Astragali, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae Flos Lonicerae, Rhizoma Coptidis, Rhizoma Curcumae, Radix Cynanchi Paniculati, the ZHONGJIEFENG PIAN) total effective rate in the clinical treatment of 79 examples that disappears of ChenBing Chu flat is 96.2%, it is 76.71 that anti-intestinalization is given birth to rate, anti-dysplasia rate 88.88%, anti-body of gland atrophy rate 73.2%.Yet the prescription of above-mentioned Chinese patent medicine is very complicated, some is wherein arranged to the human body toxic side effect since course of treatment of such disease generally at 3-5 month, so long-term prescription can produce toxic and side effects to body.
Inonqqus obliquus (Phaeoporus obliquus) (Inonotus obliquus) belongs to Basidiomycotina, Hymenomycetes, non-brown Zoopagales, Polyporaceae, brown transverse hole fungus genus, it is a kind of medicinal fungi of being born on the birch, its sporophore is the black bulk, mainly be distributed in Russia the north, Northern Europe, Japan (Hokkaido), the area that north latitude such as Changbai Mountain of China and Daxing'an Mountainrange are 40 °-50 °.This fungus is used for treating multiple disease in that Russia is among the people, and the smart powder in Pyropolyporus fomentarius (L.ex Fr.) Teng hole that Russian Komsomlshi drugmaker produces has significant curative effect to diabetes, and secular zoopery and clinical experiment show that to use Inonqqus obliquus without any side effects.
Summary of the invention
The purpose of this invention is to provide the higher treatment chronic gastritis of a kind of curative effect, medicine of gastric cancer and preparation method thereof.
The medicine of treatment chronic gastritis provided by the present invention, gastric cancer, its active component is the water extract of Inonqqus obliquus, described water extract obtains the Inonotus obliquus sporophore water 80-90 ℃ of following reflux, extract.
In order to strengthen the curative effect of medicine, can also contain the ethanol extraction of Inonqqus obliquus in the medicine, described ethanol extraction obtains with ethanol Inonotus obliquus sporophore 70-80 ℃ of following reflux, extract.Adopt water to carry the remaining Inonotus obliquus sporophore residue in back generally speaking and get final product, concentration of ethanol is advisable with 80-100%.The ratio of weight and number of the water extract of described Inonqqus obliquus and the ethanol extraction of described Inonqqus obliquus is 1.5-2.5: 1.
In needs, can also add various pharmaceutically acceptable carriers in the medicine of the present invention.Described carrier comprises diluent, excipient, filler, binding agent, wetting agent, disintegrating agent, absorption enhancer, surfactant, absorption carrier, lubricant of pharmaceutical field routine etc., can also add flavouring agent, sweeting agent etc. in case of necessity.
Amount of drug of the present invention is generally 20-30mg/ kg body weight/sky, and 3 months is a course of treatment.
The preparation method of medicine of the present invention may further comprise the steps: 1) will pulverize the Inonotus obliquus sporophore water and extract down at 80-90 ℃, and obtain aqueous extract, drying obtains water extract; 2) the last Inonotus obliquus sporophore of step 1) is refluxed down at 70-80 ℃ with ethanol, obtain ethanol extract, solvent evaporated obtains ethanol extraction; 3) with step 1) gained water extract and step 2) the gained ethanol extraction is by weight 1.5-2.5: 1 mixes, and obtains described medicine.
Wherein, step 2) described alcoholic acid concentration expressed in percentage by volume is generally 80-100%.
Each goes on foot leaching process and can adopt multiple extractionly, perhaps prolongs modes such as extraction time and improves the yield of extraction.
The present invention is based on the water extract of Inonotus obliquus sporophore, and assistant is with the active component of a certain amount of Inonotus obliquus sporophore ethanol extraction as the medicine of treatment chronic gastritis, gastric cancer, effective human body immunity improving power, and without any toxic and side effects; The zoopery of this medicine and clinical experiment confirm that this medicine has significant curative effect to gastritis, gastric cancer etc.Medicine material wide material sources of the present invention, preparation method is simple, and is with low cost, has value for clinical application and economic worth widely.
Description of drawings
Fig. 1 is that medicine of the present invention is to the mouse lymphocyte growth curve
Fig. 2 generates the influence curve of IL-2 to mouse T lymphocyte for medicine of the present invention
Fig. 3 is the influence figure of medicine of the present invention to tumor-bearing mice NK cytoactive
Fig. 4 is the inhibitory action figure of medicine of the present invention to the S-180 sarcoma
The specific embodiment
The preparation of embodiment 1, medicine of the present invention
1) Inonotus obliquus sporophore is fully pulverized after, with 90 ℃ of water extraction 48 hours, every two hours collect extracting solution therebetween one time, merge extractive liquid,, lyophilization gets black powder, is water extract, extracting yield is 46%;
2) with the sporophore behind the water extraction with 95% edible ethanol 70 ℃ of reflux, extract, 10 times, each 2 hours, merge extractive liquid,, solvent recovered under vacuum obtains ethanol extraction, extracting yield is 10%;
3) ethanol extraction and the water extract ratio of weight and number with 1: 2 is mixed, make tablet according to a conventional method, every 60mg wherein contains ethanol extraction 20mg, water extract 40mg.
The preparation of embodiment 2, medicine of the present invention
Process for preparing medicine is with embodiment 1, and difference is that the temperature of step 1) water extraction process is 80 ℃; Step 2) used concentration of alcohol is 80%, and extracting temperature is 80 ℃; The blended ratio of step 3) ethanol extraction and water extract is 1: 2.5, makes powder ampoule agent for injection according to a conventional method.
Embodiment 3, medicine of the present invention are to immune influence
1, the influence that mouse lymphocyte is bred
Get 72 of 6-8 healthy mices in age in week, be divided into 6 groups (12 every group, ♂/♀ half and half, freely gets food, drinking-water), the 1-5 group is gastric infusion 20,60,100,140,180mgkg respectively
-1D
-1The medicine of the present invention of dosage, other establishes the blank group, irritates the isopyknic physiological sodium chloride solution of stomach every day.4 mices of getting respectively in above-mentioned 6 groups in the 5th, 10,15 day after the administration are plucked the eyeball blood-letting, take off cervical vertebra and put to death, and the aseptic spleen of getting is at 37 ℃, 5%CO
2, and 84% relative humidity cultivate down, collect splenocyte, in liquid scintillation counter, measure the exit dose in each hole, according to the cell number of the standard curve unit of account volume of exit dose pair cell number, the result as shown in Figure 1.The result shows that the medicine of the present invention of 5 dosage propagation to mouse lymphocyte in three time periods of administration has different facilitations: dosage is 20mgkg
-1D
-1The time not remarkable to the facilitation of the propagation of mouse lymphocyte; And 60mgkg
-1D
-1Facilitation to the propagation of mouse lymphocyte all shows significant facilitation in three administration time sections, and presents administration time and pharmacodynamics effect positive relation; Dosage surpasses 180mgkg
-1D
-1The time, the facilitation of the propagation of mouse lymphocyte is descended.
2, to the influence of IL-2 level
Get 72 of 6-8 health KM in age in week mices, be divided into 6 groups (12 every group, ♂/♀ half and half, freely gets food, drinking-water), the 1-5 group is gastric infusion 20,60,100,140,180mgkg respectively
-1D
-1The medicine of the present invention of dosage; Other establishes the blank group, irritates the isopyknic physiological sodium chloride solution of stomach every day.Press the exit dose of mouse chest cell in the liquid flashing counting measuring diluent.The activity of IL-2 is that the size of exit dose represents that the result as shown in Figure 2 with the increment of mouse chest cell.The result shows that the medicine of the present invention of 5 dosage can promote the level that T-lymphocyte IL-2 discharges significantly.
3, the influence that mice with tumor splenocyte antibody is generated
Get 60 of KM mices, be divided into 6 groups, 5 winding kind S-180 sarcomas wherein (another group is the normal control mice).Irritate stomach 100,250 and 500mgkg respectively for 3 groups in 5 groups of tumor-bearing mices
-1D
-1The medicine of the present invention of dosage; Other establishes the blank group, irritates the isopyknic normal saline of stomach every day; Ring squama amide positive controls is irritated stomach 20mgkg every day
-1D
-1Cyclophosphamide.5 days pneumoretroperitoneum injection 0.2ml 20% sheep red blood cell (SRBC)s (about 2 * 10
9/ ml), the aseptic spleen of getting is made into 3.5 * 10 with PBS after 5 days
6/ ml splenocyte suspension adds 1 * 10 successively in clean tube
7Guinea pig serum, each 1ml of splenocyte suspension of/ml sheep red blood cell (SRBC), dilution in 1: 10,37 ℃ of water-baths 1 hour, 2000 left the heart 5 minutes, got supernatant in 413nm place mensuration absorbance.Antibody production rate=[absorbance of standard pipe absorbance-sample cell]/standard pipe absorbance * 100%.The result is as shown in table 1.
The result shows that tumor-bearing mice spleen antibody-producing capacity significantly descends; After using medicine of the present invention, tumor-bearing mice spleen antibody-producing capacity has raising significantly.
Table 1. medicine of the present invention reaches the influence that splenocyte antibody is generated to lotus tumor KM mouse lymphotactin conversion capability
*P＜0.001 (to normal mouse);
☆＜0.05;
☆ ☆P＜0.01.
4, tumor-bearing mice NK cell is killed activity influence
Get 60 of KM mices, be divided into 6 groups, 5 winding kind S-180 sarcomas wherein (another group is the normal control mice).Irritate stomach 100,250 and 500mgkg respectively for 3 groups in 5 groups of tumor-bearing mices
-1D
-1The medicine of the present invention of dosage 10 days; Other establishes the blank group, irritates the isopyknic normal saline of stomach every day; The cyclophosphamide positive controls is irritated stomach 20mgkg
-1D
-1Cyclophosphamide 10 days.The last administration is the aseptic spleen of getting after 24 hours, makes splenocyte suspension, the action effect cell; As target cell, respectively effector lymphocyte, target cell are transferred to 1 * 10 with the Hela cell with the RPMI-1640 complete medium
7/ ml, 2 * 10
5/ ml adds in 96 orifice plates, and every hole 100 μ l make the effector lymphocyte: target cell=50: 1, and laying effect cell and target cell contrast in addition, every part of specimen is established 3 parallel holes.Place 37 ℃, 5%CO
2Killed and wounded under the condition 4 hours, and added MTT (5mg/ml) 15 μ l, continued to hatch 3 hours, every hole adds 100 μ l acidify isopropyl alcohols, and piping and druming evenly dissolves purple crystal fully.In microplate reader 570nm place's photometry density (A value).The NK cytoactive is pressed the following formula formula and calculated: NK cytoactive percentage ratio=[target cell A value-(experimental group A value-effector lymphocyte A value)]/target cell A value * 100%, the result as shown in Figure 3.The NK cell is the non-specific cell in the cellular immunization, be the important executor of immunity of organism function for monitoring, play a role prior to the T cell, the non-specific killing tumor cell of its energy, its lethal effect needn't the antigen presensitization, do not need antibody to participate in yet, not limited by MHC, be body antineoplastic the first line of defence.The result shows that active having compared with normal mouse significantly of killing of tumor-bearing mice NK cell descends, and illustrates that tumor-bearing mice antineoplastic the first line of defence weakens greatly.The medicine of the present invention of three dosage is through 10 days administration, and the activity of killing of the NK cell of tumor-bearing mice has had and improves significantly and surpass the normal control Mus.
5, to the influence of immune organ
Get 60 of KM mices, be divided into 6 groups, 5 winding kind S-180 sarcomas wherein (another group is the normal control mice).Irritate stomach 100,250 and 500mgkg respectively for 3 groups in 5 groups of tumor-bearing mices
-1D
-1The medicine of the present invention of dosage 10 days; Other establishes the blank group, irritates the isopyknic normal saline of stomach every day; Ring squama amide positive controls is irritated stomach 20mgkg
-1D
-1 Ring squama amide 10 days.Killed mice in 24 hours after the last administration, get spleen, thymus, calculate thymus index and index and spleen index according to a conventional method, the result is as shown in table 2.Tumor-bearing mice is because the formation of tumor makes immune organ littler than normal mouse.The result shows that medicine of the present invention can obviously improve the thymus index and the index and spleen index of tumor-bearing mice, and observes dose-effect positive relation in test dose.
Table 2. medicine of the present invention is to the influence (n=10) of tumor-bearing mice immune organ
☆P＜0.05 (to normal mouse);
*P＜0.05 is (to S
180Tumor-bearing mice).
Embodiment 4, medicine extracorporeal anti-tumor cytoactive of the present invention
Medicine of the present invention dissolves with DMSO, and making its final concentration with the preparation of RPM I-1640 culture medium is 100,250,500 μ g/ml.At 37 ℃, 5%CO
2Environment in cultivated 24 hours, press MTT method detection medicine of the present invention to the Hela cell, hepatoma carcinoma cell SMMC7721, stomach cancer cell MGC-803, splenocyte, the toxicity of tire mouse fibroblast cell, the result is as shown in table 3.The result shows that medicine of the present invention has significant cytotoxicity to tumor cell Hela cell, hepatoma carcinoma cell SMMC7721 and stomach cancer cell MGC-803, and wherein the suppression ratio of high dose group reaches more than 90%; And very low to the toxicity of fibroblast, lymphocyte (splenocyte), illustrate that medicine of the present invention has selection toxicity to tumor cell.
Table 3. medicine of the present invention to tumor cell and Normocellular toxicity (mtt assay, suppression ratio %, n=5)
Embodiment 5, medicine of the present invention are to H
22The inhibitory action of solid tumor mouse tumor
Get 60 of KM mices, be divided into 5 groups, inoculate H respectively
22Solid tumor.In the tumor-bearing mice 3 groups with 100,250 and 500mgkg
-1D
-1Dosage irritated stomach medicine of the present invention 14 days.Other establishes the normal saline matched group; With the 5-fluorouracil positive controls, dosage is 20mgkg
-1D
-1The last administration is got solid tumor after 24 hours and is weighed, and calculates tumour inhibiting rate, and the result is as shown in table 4.The result shows that medicine of the present invention is to H
22Sarcoma has inhibitory action significantly, and dosage is 500mgkg
-1D
-1Medicine inhibitory rate 73.3% of the present invention, surpass classical cancer therapy drug 5-fluorouracil.
Table 4 medicine of the present invention is to H
22The inhibitory action of solid tumor mouse tumor (n=10)
Compare with the normal saline matched group,
*P＜0.01,
*P＜0.001.
Embodiment 6, to the inhibitory action of S-180 sarcoma
Get 60 of KM mices, be divided into 5 groups, inoculate the S-180 sarcoma respectively.In the tumor-bearing mice 3 groups with 100,250 and 500mgkg
-1D
-1Dosage irritated stomach 10 days.Other establishes the blank group, irritates the normal saline of stomach equal volume; Cyclophosphamide-a control group, dosage are 20mgkg
-1D
-1The last administration was killed mice after 24 hours, got sarcoma and weighed, and the result as shown in Figure 4.The result shows that medicine of the present invention has inhibitory action significantly to the S-180 sarcoma, and dosage is 500mgkg
-1D
-1Medicine inhibitory rate 59.5% of the present invention, surpass classical cancer therapy drug cyclophosphamide.
Embodiment 7, medicine of the present invention are to short apoptosis of tumor cells Bax gene and but apoptosis of tumor cells Bcl-2 gene expression influence
Apoptosis is the basic process of tumor mortality, also is the basic process that antitumor drug causes tumor mortality.The gene relevant with apoptosis has bcl-2 and bax gene, and wherein bcl-2 suppresses apoptosis gene, and bax promotes apoptosis gene.Apoptosis depends on ratio and other anti-apoptotic proteins of bcl-2 and bax, the modes such as bcl-2/bcl-2, bcl-2/bax and bax/bax that have of bcl-2 and bsx.
Get 60 of KM mices, be divided into 5 groups, inoculate the S-180 sarcoma respectively, in the tumor-bearing mice 3 groups with 100,250 and 500mgkg
-1D
-1Dosage irritated stomach 10 days.Other establishes the blank group, irritates the normal saline of stomach equal volume; Cyclophosphamide-a control group, dosage are 20mgkg
-1D
-1The result is as shown in table 4.
The result shows that in the normal saline matched group, tumor-bearing mice is based on bcl-2 gene expression; And medicine of the present invention can obviously strengthen bax gene expression, and is dose-dependence, illustrates that medicine of the present invention has remarkable inhibitory action to S-180.
Table 4 medicine of the present invention is to influence (positive particle number/4 * 4mm) of S-180 sarcoma bax/bcl-2 gene expression
Embodiment 8, to the treatment of chronic gastritis
Medicine of the present invention is treated 79 routine chronic gastritis patients (40 routine superficial gastritis patients, 39 routine atrophic gastritis patients), takes medicine three times by per kilogram of body weight 10mg dosage branch every day, and 3 months was 1 course of treatment, withdrew other drug during the treatment.The result shows: symptoms such as among the 40 routine superficial gastritis patients, 39 routine private prosecutions have stomach discomfort, stomachache, feel sick, just improved at second day that takes medicine, and 1 example improves in the 5th day symptom of taking medicine, and the course of treatment of taking medicine, symptom is eliminated substantially.Before the 39 routine atrophic gastritis patient treatments, companion's intestinal gland metaplasia 20 examples, companion I degree atypical hyperplasia 13 examples, slight atrophy 6 examples; Medication treatment 1 month, 20 example companion intestinal gland metaplasia symptoms are obviously improved, and 12 routine atypical hyperplasias, the slight atrophy of 6 examples all disappear, and total effective rate is 100%.
Embodiment 9, to the treatment of gastric cancer
With medicine of the present invention is the main treatment medicine, and 26 routine patients with gastric cancer are treated, and takes medicine three times by per kilogram of body weight 10mg dosage branch every day, and 3 months was 1 course of treatment, generally need take 2 courses of treatment, checked gastroscope half a year No. 1 time.Criterion of therapeutical effect: 1. produce effects: clinical symptom disappearance or basic the disappearance, gastroscopy pathology report intestinal epithelial metaplasia and atypical hyperplasia disappear or alleviate more than 2 level degree; 2. effective: clinical symptoms obviously alleviates, and gastroscopy pathology report intestinal epithelial metaplasia and atypical hyperplasia alleviate more than 1 level degree; 3. invalid: clinical symptoms does not have improvement, gastroscopy pathology report no change.Treatment is organized in 26 examples, 12 routine produce effects, and 13 examples are effective, invalid 1 example, total effective rate 96.15%.
Claims (6)
1. medicine for the treatment of chronic gastritis, gastric cancer, its active component is Inonqqus obliquus water extract and Inonqqus obliquus ethanol extraction; Described water extract extracts the Inonotus obliquus sporophore water down at 80-90 ℃ and obtains; Described ethanol extraction obtains with ethanol Inonotus obliquus sporophore 70-80 ℃ of following reflux, extract; The ratio of weight and number of described water extract and ethanol extraction is 1.5-2.5: 1.
2. medicine according to claim 1 is characterized in that: the Inonotus obliquus sporophore that is used to extract described Inonqqus obliquus ethanol extraction is the sporophore after carrying through described water.
3. medicine according to claim 1 and 2 is characterized in that: described concentration of ethanol is 80-100%.
4. according to claim 1 or 2 or 3 described medicines, it is characterized in that: the effective dose of described medicine is 20-30mg/ kg body weight/sky.
5. the preparation method of the described medicine of claim 2 may further comprise the steps: 1) will pulverize the Inonotus obliquus sporophore water and reflux down at 80-90 ℃, and obtain aqueous extract, drying obtains water extract; 2) the last Inonotus obliquus sporophore of step 1) is refluxed down at 70-80 ℃ with ethanol, obtain ethanol extract, solvent evaporated obtains ethanol extraction; 3) with step 1) gained water extract and step 2) gained ethanol extraction 1.5-2.5 by ratio of weight and the number of copies: 1 mixes, and obtains described medicine.
6. preparation method according to claim 5 is characterized in that: step 2) described concentration of ethanol is 80-100%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100708435A CN100406026C (en) | 2004-07-23 | 2004-07-23 | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100708435A CN100406026C (en) | 2004-07-23 | 2004-07-23 | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1723956A CN1723956A (en) | 2006-01-25 |
| CN100406026C true CN100406026C (en) | 2008-07-30 |
Family
ID=35923672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100708435A Expired - Fee Related CN100406026C (en) | 2004-07-23 | 2004-07-23 | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100406026C (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102533515B (en) * | 2010-12-15 | 2013-06-19 | 詹跃勇 | Health-care wine prepared from fuscoporia oblique |
| CN102579511B (en) * | 2012-03-13 | 2013-11-27 | 天津大学 | Method for integrally extracting steroidal compounds, polysaccharides and polyphenols from inonotus obliquus |
| CN103142661B (en) * | 2013-04-02 | 2015-01-14 | 金波 | Preparation method of inonqqus obliquus water-extract fine powder |
| CN103690572B (en) * | 2013-12-17 | 2017-01-04 | 杨庆贺 | Preparation method of inonotus obliquus tea powder |
| CN104004106A (en) * | 2014-04-28 | 2014-08-27 | 杨庆贺 | Method for extracting effective substances in inonotus obliquus and preparation method for teabag |
| CN114617906A (en) * | 2020-12-14 | 2022-06-14 | 黑龙江儒泰科技发展有限责任公司 | Preparation method and application of inonotus obliquus extract |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010025337A (en) * | 2000-12-16 | 2001-04-06 | 정종상 | A method of preparing the antitumor and immuno-activity polysaccharide from the artificial cultivation of inonotus obliquus, and its use |
| CN1398902A (en) * | 2002-05-21 | 2003-02-26 | 崔基成 | Extraction process of Fuscoporia obliqua polysaccharide |
| KR20030083252A (en) * | 2002-04-19 | 2003-10-30 | (주)허벤텍 | Compositions Comprising Extracts of Chaga Fungus And The Use Thereof |
| KR20030083251A (en) * | 2002-04-19 | 2003-10-30 | (주)허벤텍 | Extracts of Chaga Fungus And Stomach Inflammatory Agent Containing The Same |
| KR20040042119A (en) * | 2002-11-13 | 2004-05-20 | 주식회사 엔바이오테크놀러지 | Composition having immune-enhancing and anticancer activity comprising the extracts of CHAGA mushroom |
-
2004
- 2004-07-23 CN CNB2004100708435A patent/CN100406026C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010025337A (en) * | 2000-12-16 | 2001-04-06 | 정종상 | A method of preparing the antitumor and immuno-activity polysaccharide from the artificial cultivation of inonotus obliquus, and its use |
| KR20030083252A (en) * | 2002-04-19 | 2003-10-30 | (주)허벤텍 | Compositions Comprising Extracts of Chaga Fungus And The Use Thereof |
| KR20030083251A (en) * | 2002-04-19 | 2003-10-30 | (주)허벤텍 | Extracts of Chaga Fungus And Stomach Inflammatory Agent Containing The Same |
| CN1398902A (en) * | 2002-05-21 | 2003-02-26 | 崔基成 | Extraction process of Fuscoporia obliqua polysaccharide |
| KR20040042119A (en) * | 2002-11-13 | 2004-05-20 | 주식회사 엔바이오테크놀러지 | Composition having immune-enhancing and anticancer activity comprising the extracts of CHAGA mushroom |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1723956A (en) | 2006-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103861079B (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN101491663B (en) | Traditional Chinese medicine composition for treating various cancer | |
| CN100490789C (en) | Enteric coated Chinese medicinal capsule for treating cancer and preparation method thereof | |
| CN102008650B (en) | Compound traditional Chinese medicine preparation for treating tumors and preparation method thereof | |
| CN102861284B (en) | Traditional Chinese medicine compound preparation for treating non-small cell lung cancer and preparation method thereof | |
| CN103386078B (en) | A kind of Chinese medicine composition is preparing the application in treating colon cancer drug | |
| CN101850032B (en) | Anti-tumor traditional Chinese medicine composition and preparation method and application thereof | |
| CN102764371B (en) | Traditional Chinese medicine compound prescription for relieving radiotherapy side reactions and preparation method and application thereof | |
| CN100406026C (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN102028924B (en) | Medicinal composition for late gastric cancer | |
| CN103933450A (en) | Traditional Chinese medicine composition for preventing or/and treating gastrointestinal diseases and preparation method of composition | |
| CN108186794B (en) | Traditional Chinese medicine composition for treating lung cancer and preparation method and application thereof | |
| WO2018171672A1 (en) | Anti-cancer pharmaceutical composition and use thereof | |
| CN102078600B (en) | Anti-cancer compound ganoderma composition, application thereof and pharmaceutical composition containing same | |
| CN104324316A (en) | Application of traditional Chinese medicine composition to prepare medicines treating colorectal cancer | |
| CN113304226A (en) | Traditional Chinese medicine composition for treating lung cancer | |
| CN112022896A (en) | Anti-tumor traditional Chinese medicine compound soft capsule preparation and preparation method and application thereof | |
| CN100556448C (en) | Chinese medicine pharmaceutical composition of a kind of inhibition and treatment tumor and its production and application | |
| CN104784651B (en) | A kind of method for preparing the pharmaceutical preparation for treating gastric ulcer | |
| CN115154576B (en) | Traditional Chinese medicine composition for treating malignant tumor-associated diarrhea | |
| CN106619870A (en) | Composition for treating digestive system neoplasms, and preparation method of composition | |
| CN107019771A (en) | A kind of antineoplastic Chinese medicine composition | |
| CN104398704A (en) | Traditional Chinese medicine composition for treating stomach cancer and preparation method thereof | |
| CN1122523C (en) | Medicine for curing malignant tumor and its preparation method | |
| US20190262413A1 (en) | Composition of combined plant proteins for treatment of cancer and diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080730 Termination date: 20130723 |